Safety verification trials of mFOLFIRI and sequential IRIS + bevacizumab as first- or second-line therapies for metastatic colorectal cancer in Japanese patients on behalf of tohoku clinical oncology research and education

Oncology (Switzerland)

Volumn 83, Issue 2, 2012, Pages 101-107

  Kato, Shunsuke ^a   Andoh, Hideaki ^e   Gamoh, Makio ^f   Yamaguchi, Takuhiro ^b   Murakawa, Yasuko ^g   Shimodaira, Hideki ^a   Takahashi, Shin ^a   Mori, Takahiro ^c   Ohori, Hisatsugu ^a   Maeda, Shun Ichi ^h   Suzuki, Takao ^d   Kato, Satoshi ⁱ   Akiyama, Shoko ^a   Sasaki, Yuka ^b   Yoshioka, Takashi ^j   Ishioka, Chikashi ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOHOKU UNIVERSITY HOSPITAL   (Japan)

^d SENDAI CITY MEDICAL CENTER   (Japan)

^e Nakadori General Hospital   (Japan)

^f South Miyagi Medical Center   (Japan)

^g Miyagi Cancer Center   (Japan)

^h Hachinohe City Hospital   (Japan)

ⁱ Iwate Prefectural Central Hospital   (Japan)

^j YAMAGATA UNIVERSITY   (Japan)

more..

Author keywords

Advanced colorectal cancer; Bevacizumab; Irinotecan; Randomized trial; S 1

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BLEEDING; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COLORECTAL CANCER; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HISTOLOGY; HUMAN; HYPERTENSION; JAPANESE; LEUKOPENIA; MAJOR CLINICAL STUDY; METASTASIS; MUCOSA INFLAMMATION; NEUTROPENIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RECURRENT CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED;

EID: 84863505244     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000339541     Document Type: Article

References (20)

1. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM, McWilliams RR: Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009; 27: 3677-3683.
2. Hurwitz H, Fehrenbacher L, Novothy W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2325-2342.
3. Saltz LB, Clark S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J: Bevacizumab in combination with oxaliplatin- based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
4. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol 2007; 25: 4779-4786. (Pubitemid 350086481)
5. Hurwits H, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23: 3502-3508.
6. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D; First BEAT investigators: safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009; 20: 1842-1847.
7. Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, Ashby MA, Dong W, Sugrue MM, Grothey A, investigators of the BRiTE study: clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer. The BRiTE observational cohort study. Oncologist 2009; 14: 862-870.
8. Groeger JS, Lucas AB, Thaler HT, Friedlander- Klar H, Brown AE, Kiehn TE, Armstrong D: Infectious morbidity associated with long-term use of venous access devices in patients with cancer. Ann Intern Med 1993; 119: 1168-1174. (Pubitemid 23361446)
9. Verso M, Agnelli G: Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003; 21: 3665-3675. (Pubitemid 46594061)
10. Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Saltz L: Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26: 2006-2012.
11. Shirasaka T, Nakano K, Takeuchi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N, Fukushima M: Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996; 56: 2602-2606. (Pubitemid 26171684)
12. Shirao K, Ohtsu A, Takada H, Mitachi Y, Hirakawa K, Horikoshi N, Okamura T, Hirata K, Saitoh S, Isomoto H, Satoh A: Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. Cancer 2004; 100: 2355-2361. (Pubitemid 38657882)
13. Yamada Y, Tahara M, Miya T, Satoh T, Shirao K, Shimada Y, Ohtsu A, Sasaki Y, Tanigawara Y: Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer. Br J Cancer 2008; 98: 1034-1038. (Pubitemid 351399808)
14. Goto A, Yamada Y, Yasui H, Kato K, Hamaguchi T, Muro K, Shimada Y, Shirao K: Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. Ann Oncol 2006; 17: 968-973. (Pubitemid 43778988)
15. Yoshioka T, Kato S, Gamoh M, Chiba N, Suzuki T, Sakayori N, Kato S, Shibata H, Shimodaira H, Otsuka K, Kakudo Y, Takahashi S, Ishioka C: Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer. Br J Cancer 2009; 101: 1972-1977.
16. Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, Satoh T, Denda T, Ina K, Nishina T, Yamaguchi K, Takiuchi H, Esaki T, Tokunaga S, Kuwano H, Komatsu Y, Watanabe M, Hyodo I, Morita S, Sugihara K: Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomized phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 2010; 11: 853-860.
17. Sasaki M, Ohtsu A, Shimada Y, Ono K, Saijo N: Simultaneous administration of CPT-11 and fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. J Natl Cancer Inst 1994; 86: 1096-1098. (Pubitemid 24228479)
18. Falcone A, Di Paolo A, Masi G, Allegrini G, Danesi R, Lencioni M, Pfanner E, Comis S, Del Tacca M, Conte P: Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapynaï ve metastatic colorectal cancer patients. J Clin Oncol 2001; 19: 3456-3462. (Pubitemid 32730081)
19. Machin D, Campbell MJ, Tan SB, Tan SH: Sample Size Tables for Clinical Studies, ed 2. Oxford, Blackwell, 1997.
20. Yamada Y, Yamaguchi T, Matsumoto H, Ichikawa Y, Goto A, Kato K, Hamaguchi T, Shimada Y: Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as firstline therapy for patients with metastatic colorectal cancer. Invest New Drugs 2011, Epub ahead of print.